ESC® 2025 – ATTRibute-CM: Sustained Benefits of Acoramidis in Cardiac Amyloidosis
Dr. Michael Gibson interviews Dr. Kevin Alexander on the continued benefits of acoramidis. Results from 42 months reinforce the importance of timely therapy initiation in the management of cardiac amyloidosis.
TribeMD
3 min read
September 2, 2025
Carregando conteúdo…
Cardiology
ESC 2025
Highlights
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
ASCO GU® 2026
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care